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We have recently demonstrated that the anti-proliferative
effect of interferon (IFNg) in RCC is due to an increased
production of nitric oxide (NO) which in turn inhibits the
induction of arginase (ARG2). The growth of cultured
murine RCC cell lines was inhibited in 85% in IFNg trea-
ted when compared to un-treated cells. In contrast only
33% of these cells were inhibited by IFNg. These results
indicate that even though IFNg show a more potent
anti-proliferative effect, still there is a certain degree of
treatment- resistance (15%) that is higher when cells are
treated with IFNg. This study was undertaken to study the
mechanisms by which IFNg inhibits RCC growth and to
provide new insights in understanding how this cytokine
alone or in combination with other therapies could benefit
RCC clinical outcome. Cell survival, cell cycle arrest-
apoptosis and cell signaling targets were identified by
MTT assay, flow cytometry and immunoblotting respec-
tively in RCC cell lines CL-2 (low-ARG/low-iNOS), CL-19
(high-ARG/low iNOS) and Renca (med-ARG/zero-iNOS).
The results showed that 1-100 U/ml IFNg suppressed
proliferation of both CL-2 and CL-19 in a dose- and time-
dependent manner. IFNg inhibited the growth of CL 2 and
CL 19 tumor cells with IC50-values of 10.2 ± 1.5 U/ml
and 13.5 ± 1.0 U/ml, respectively. There was no inhibition
of growth in the Renca cell line. The results on cell cycle
progression have shown that the anti-proliferative effect of
IFNg is associated with a G2/M cell cycle arrest of CL-2
and CL-19 cells. The event of cell cycle arrest was
associated with a marked decline in protein levels of
G2/M regulatory proteins cyclin B1, cyclin A and cyclin-
dependent kinase 1 (Cdk1/cdc2), whereas an up-regulation
in CDC25c was observed. Elimination of IFNg resulted
in increased tumor growth that was contained with the
sustained addiction of the cytokine. No apoptosis was
observed. Our study demonstrated that IFNg suppress the
growth of murine RCC cells by inducing cell-cycle arrest
at G2/GM through the down-regulation of cyclin B1 and
cyclin C. These findings suggest that IFNg acts as an
effective anti-proliferative agent by modulating cell growth
regulators in renal carcinoma cells and can be used as a
election treatment to inhibit tumor proliferation in
patients scheduled for surgery.
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